Diagnostic Usefulness of Interferon Gamma Release Assay for Active Tuberculosis in Immunocompromised Patients
Information source: Yonsei University
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Tuberculosis
Phase: N/A
Status: Recruiting
Sponsored by: Yonsei University
Summary
For diagnosis of active tuberculosis, interferon-γ release assay based mycobacterium
tuberculosis specific antigen may show higher sensitivity than tuberculin skin test in
immunocompromised patients. Therefore, interferon-γ release assay have a role as a rapid
diagnostic adjunctive methods for active tuberculosis in immunocompromised patients.
Clinical Details
Study design: Other, Other
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patient suspicious of active tuberculosis with immunocompromised condition
- Immunocompromised condition patients with
1. solid cancer with chemotherapy
2. hematologic malignancy
3. organ transplantation
4. immunosuppressant
5. ESRD on renal replacement therapy
6. Diabetes
7. advanced liver cirrhosis
Exclusion Criteria:
- Patients with
1. less than 20 years
2. who don't agree the participation of study
3. hypersensitivity history to tuberculin
4. pregnancy
Locations and Contacts
Yonsei Univ., Seoul, Korea, Republic of; Recruiting
Se Kyu Kim, Ph.D, Phone: 82-10-8772-7095, Email: sekyukim@yuhs.ac
Se Kyu Kim, Ph.D, Principal Investigator
Additional Information
Starting date: July 2009
Last updated: September 11, 2009
|
